Access read The cheapest option in retina medicine has just become a branded product, and the number that decides whether this works has not been disclosed. Compounded bevacizumab is used in most first-line wet AMD treatment for one reason: it costs a small fraction of the branded anti-VEGF agents, which is why an entire treatment paradigm was built on an off-label workaround. Outlook now has to price a regulated version of that same molecule, and the framing in its own release, an $8.5 billion market and a new standard of care, is not how a company describes a product it intends to sell at compounding prices. Note also what the exclusivity does and does not do. Twelve years under the BPCIA blocks biosimilar applications referencing LYTENAVA; it does not stop compounding pharmacies continuing to repackage intravenous bevacizumab as they have since 2005. So this is not a product replacing a cheaper rival, it is a regulated product asking physicians and payers to pay a premium for manufacturing consistency, approved labelling and FDA oversight on a molecule they have used cheaply for twenty years. That is a genuine value proposition and an unproven willingness to pay. Watch the launch price and the first payer coverage decisions, because they will settle whether this expands access or quietly raises the cost of the one affordable option in the field.